Study register · detail
Unclear
GRADE
High
136 citations
SampleSystematische Review
Durationup to May 2019
EndpointPTSD symptomatology
Blindingunklar
DesignSystematic Review
Key finding
Cannabis and synthetic cannabinoids show potential therapeutic benefit for improving PTSD symptoms, but current evidence regarding safety and efficacy is limited.
Summary
Systematic review of medical cannabis and synthetic cannabinoids in PTSD (PRISMA-compliant, PubMed/Cochrane/Web of Science up to May 2019). Cannabis and synthetic cannabinoids show therapeutic potential for improving PTSD symptoms (anxiety reduction, modulation of memory-associated processes, sleep improvement) through action on the endocannabinoid system. Evidence on safety and efficacy is currently limited; further research is required.
P
PopulationAdults with PTSD
I
InterventionMedical cannabis and synthetic cannabinoids
O
OutcomeCannabis and synthetic cannabinoids show potential therapeutic benefit for PTSD symptoms (anxiety reduction, memory modulation, sleep improvement); however, the evidence base is limited
Confidence in the evidence
High
The highest of four GRADE levels, the effect estimate is very reliable.
Quality profile
Sample size
—
Blinding
—
Effect size
—
Citations / year
★★★★★
Authors
Share
Abstract
Background And Objectives: Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives for the treatment of this condition. The present paper aims to evaluate the clinical and therapeutic potentials of medical cannabis and synthetic cannabinoids in treating PTSD patients.
Methods: A systematic electronic search was performed, including all papers published up to May 2019, using the following keywords (((cannabis[Title/Abstract]) OR (synthetic cannabinoids [Title/Abstract])) AND ((PTSD[Title/Abstract]) OR (Posttraumatic stress disorder[Title/Abstract]))) for the topics 'Cannabis', 'Synthetic Cannabinoids', 'PTSD', and MESH terms, on the PubMed, Cochrane Library, and Web of Science online databases. For data gathering purposes, PRISMA guidelines were followed. Results were organized into two groups, considering cannabis and synthetic cannabinoids as different therapeutic approaches for
Ptsd. Results: Present data show that cannabis and synthetic cannabinoids, both acting on the endocannabinoids system, may have a potential therapeutic use for improving PTSD symptoms, e.g., reducing anxiety, modulating memory-related processes, and improving sleep.
Conclusions: Even though the current literature suggests that cannabis and synthetic cannabinoids may have a role in the treatment of PTSD, there is currently limited evidence regarding their safety and efficacy. Therefore, additional research is needed in order to better understand the effectiveness and therapeutic usage of these drug classes and monitor their safety.
The impediment to action advances action.